🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Always enjoy discussing the data and the science at the poster sessions. Great to see so many friends at #ASCO25 Sanjay Popat Jorge Alatorre Alexander Nasser Hanna Clarissa Mathias Marco Tagliamento Kelly Meza, MD Hossein Borghaei, DO Thomas Wu

Love to see my “former” fellows, current colleagues and friends at ASCO. So happy to see them being so successful.#ASCO, #FoxChaseCancer ⁦Fox Chase Cancer Center⁩

Great friends and a very nice poster session. Lots of great trials in progress and interesting translational work.

Hossein Borghaei, DO Fox Chase Cancer Center Another former fellow here! 🙌🏽✋🏽

Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in NEJM Presentation today by 1@only Charlie Rudin #ASCO25

Temab-A; n=41 EGFR ; widespread activity with met exp and other mutations. I’m not sure 15% discontinuation rate due to gd3 or greater tox is that manageable? #ASCO25

ABBV-400 a new antiMET ADC tested in pretreated EGFRm NSCLC reported ORR 26% and DoR 9.8 regardless cMET expression. It is a crowded space with BL-B01D1, DB-1310, dual TKI EGFR/ET etc. Can we ⬆️ ABBV-400 combining with osimertinib?TelisoV + Osi > Teliso alone in mEGFR 🫁#ASCO25

Telisotuzumab adizutecan (ABBV-400, Temab-A) in #EGFR NSCLC at #ASCO25. This is a cMET ADC like Teliso-V but with a topoisomerase 1 inhibitor. Safety notable for myelosuppression, 7% pneumonitis (1 fatal). RR 63%, DOR 9.8m, PFS 10.9m.

Proud to see Dr Padda presenting the results of the S1900E. This is yet another example of how we can all come together and conduct national trials in rare subtypes of NSCLC and answer important questions quickly. #lungmap , #ASCO , #FoxChaseCancer

Hossein Borghaei, DO Sanjay Popat Exactly

Stephen V Liu, MD Oncology Brothers Kristin Higgins Nathan A. Pennell MD, PhD, FASCO Dr Riyaz Shah gilberto lopes Narjust Florez, MD, FASCO Aakash Desai, MD, MPH, FASCO Alfredo Addeo MD Dr. Amy C. Moore Christian Rolfo Charu Aggarwal, MD, MPH, FASCO Dr. Estela Rodriguez Sandip Patel MD FASCO Sanjay Popat Dr. Nagla Abdel Karim Hossein Borghaei, DO Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Hidehito HORINOUCHI Dr. Bosch-Barrera Marina Garassino

🔥🚨OncoAlert Hot Off The Press Just published The Lancet In conjunction with presentation ASCO #ASCO25 ✅Results of #IMforte trial of: #Lurbinectedin + #Atezolizumab as 1st line #Maintenance Tx in #Patients with #ExtensiveStage #SmallCell #LungCancer. 👇🏻

#ASCO25 Dr. Charlie Rudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

3 SCLC positive trials 🎉 We are celebrating here. #ASCO2025

It was a great pleasure to witness the signing of collaboration between the Egyptian Cancer Society #ECS and The American Cancer Society ⁦ASCO⁩ #ASCO25 I was a member of #ECS since 1995 folowed by 20 years of membership at ASCO. Happy to be part of it.

Hossein Borghaei, DO Stephen V Liu, MD My main question concerns the long half-life of IO: perhaps the timing of the first dose (D1C1) is what truly matters, since IO concentrations remain high even at three weeks, making subsequent dosing less sensitive to timing.

Proud to be part of the IMforte effort - the first phase 3 maintenance study in #SCLC to show a survival benefit with an OS HR 0.73 - grateful to the team Luis Paz-Ares Hossein Borghaei, DO Solange Peters Roy Herbst Melissa L. Johnson Raffaele Califano Martin Reck thelancet.com/journals/lance…

Discussing lung cancer data from #ASCO25 with colleagues Frank Griesinger Michael Thomas Dr Riyaz Shah Hossein Borghaei, DO Lizza Hendriks Noemi Reguart Nicolas Girard with high5md - recording available soon!

The new exhibit in the lobby of Fox Chase Cancer Center is terrific — from the discovery of the Philadelphia Chromosome to the two-hit hypothesis to Nobel Prize-winning breakthroughs, it honors a legacy that absolutely redefined cancer care. Built on this foundation, FCCC continues to